Hikma Pharmaceuticals Share Price (HIK)

1,870.75 -9.75 (-0.52%) delayed: 12:09PM BST
Bid price 1,869.50 Open price 1,875.50
Ask price 1,872.00 Prev close 1,880.50
High price 1,893.75 Spread 0.13%
Low price 1,866.50 Volume 58,688

Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.

Hikma Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Hikma Pharmaceuticals share price charts

Hikma Pharmaceuticals Share Price Information

Name Hikma Pharmaceuticals Epic HIK
Sector Pharmaceuticals & Biotechnology ISIN GB00B0LCW083
Activites Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. Index FTSE 250

Hikma Pharmaceuticals Key Numbers

Latest Share Price (p) 1,870.75 Net Gearing (%) 48.20
Market Capitalisation (£m) 4,539.96 Gross Gearing (%) 54.90
Shares in issue (m) 241.42 Debt Ratio 41.03
P/E Ratio -5.35 Debt-to-Equity Ratio 0.57
Total dividends per share (p) 34.00 Assets / Equity Ratio 2.22
Dividend Yield (%) 1.19 Price to book value 2.97
Dividend cover (x) 0.00 ROCE (%) -28.48
Earning per share (p) -351.80 EPS Growth (%) -629.02
52 week high / low 2,033.00 / 814.20 DPS Growth (%) 3.03

Hikma Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
30/05/2018 BUY Sigurdur Olafsson CEO 20,000
23/05/2018 BUY John Castellani NED 1,000
15/05/2018 TIN Mazen Darwazah ED 20,000
15/05/2018 TIN Said Darwazah CH 27,000
19/03/2018 TIN Mazen Darwazah ED 38,501

More Hikma Pharmaceuticals Director Deals >>

Hikma Pharmaceuticals Company News

11:05 03/09/2018

Total Voting Rights

RNS Number : 5756Z Hikma Pharmaceuticals Plc 03 September 2018     Hikma Pharmaceuticals PLC Total Voting Rights and Capital   LONDON, 3 September 2018 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals...

09:58 30/08/2018

Holding(s) in Company

RNS Number : 2675Z Hikma Pharmaceuticals Plc 30 August 2018   TR-1: S tandard form for notification of major holdings   LONDON, 30 August 2018 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) announces the below, which is an...

12:45 28/08/2018

Holding(s) in Company

RNS Number : 0240Z Hikma Pharmaceuticals Plc 28 August 2018   TR-1: S tandard form for notification of major holdings   LONDON, 28 August 2018 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) announces as follows:...

More Hikma Pharmaceuticals Company News >>

Register now for FREE Hikma Pharmaceuticals company news

Hikma Pharmaceuticals Share Price Discussions

more than 1 year ago

Hikma Pharmaceuticals (HIK)

Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...

Register now for FREE Hikma Pharmaceuticals share price discussions